Trials / Completed
CompletedNCT03829514
Fenofibrate in Type 2 Diabetes
Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fenofibrate | 40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up. |
Timeline
- Start date
- 2019-02-04
- Primary completion
- 2020-03-04
- Completion
- 2020-03-04
- First posted
- 2019-02-04
- Last updated
- 2023-10-24
- Results posted
- 2022-02-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03829514. Inclusion in this directory is not an endorsement.